5-Jun-2026
BTIG Sticks to Its Hold Rating for PROCEPT BioRobotics (PRCT)
TipRanks (Wed, 3-Jun 7:30 AM ET)
TipRanks (Wed, 3-Jun 7:30 AM ET)
TipRanks (Wed, 3-Jun 7:24 AM ET)
Globe Newswire (Thu, 28-May 8:00 AM ET)
AUA Guidelines Strengthen Recommendation for Aquablation Therapy
Globe Newswire (Thu, 14-May 8:00 AM ET)
PROCEPT BioRobotics to Attend Three Upcoming Investor Conferences in May & June
Globe Newswire (Thu, 30-Apr 4:03 PM ET)
PROCEPT BioRobotics Reports First Quarter 2026 Financial Results
Globe Newswire (Wed, 29-Apr 4:03 PM ET)
Business Wire (Wed, 22-Apr 5:00 PM ET)
Business Wire (Wed, 22-Apr 3:00 PM ET)
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Procept Biorobotics trades on the NASDAQ stock market under the symbol PRCT.
As of June 5, 2026, PRCT stock price climbed to $27.83 with 984,940 million shares trading.
PRCT has a beta of 0.34, meaning it tends to be less sensitive to market movements. PRCT has a correlation of 0.01 to the broad based SPY ETF.
PRCT has a market cap of $1.58 billion. This is considered a Small Cap stock.
Last quarter Procept Biorobotics reported $83 million in Revenue and -$.56 earnings per share. This beat revenue expectation by $3 million and met earnings estimates .
In the last 3 years, PRCT traded as high as $103.81 and as low as $19.35.
The top ETF exchange traded funds that PRCT belongs to (by Net Assets): VTI, IWM, VB, VBK, VXF.
PRCT has underperformed the market in the last year with a price return of -57.2% while the SPY ETF gained +25.6%. However, in the short term, PRCT had mixed performance relative to the market. It has outperformed in the last 3 months, returning +9.8% vs +8.5% return in SPY. But in the last 2 weeks, PRCT shares have been beat by the market, returning -4.0% compared to an SPY return of -1.1%.
PRCT support price is $25.75 and resistance is $28.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRCT shares will trade within this expected range on the day.